Warning: session_start() expects parameter 1 to be array, string given in /home/k11lqezc/test.toscanalifesciences.org/wp-includes/class-wp-hook.php on line 286 BiOMViS Srl - Toscana Life SciencesBiOMViS Srl - Toscana Life Sciences
BiOMViS Srl is a Biotech Company founded in 2018 to foster prophylactic and immunotherapeutic interventions in infectious diseases and cancer.
The Company has two main objectives:
1. Development of innovative OMV-based vaccines against infectious diseases and cancer OMVs are closed spheroid particles released by Gram-negative bacteria which are particularly attractive as vaccine platform for three main features:
they carry potent stimulators (adjuvants) of the immune system
they can be efficiently decorated with foreign antigens
they can be easily purified from bacterial culture supernatant
Thanks to their built-in adjuvanticity and antigen-delivery capacity, OMVs engineered with heterologous antigens can elicit remarkable protective humoral and cell-mediated immune responses against infectious diseases and cancer. BiOMViS’ technology of OMV engineering and preparation is particularly attractive for both anti-microbial vaccines and personalized cancer vaccines. Personalized cancer vaccines are constituted by tumor-specific antigens generated by gene mutations, and by immunostimulatory components (“adjuvants”). Since mutations are tumor- and patient-specific, cancer vaccines must be personalized. The production of personalized cancer vaccines involves:
collection of cancer biopsies from patient,
whole genome/exome sequencing of cancer cells,
bioinformatics identification of cancer-associated mutations and prediction of cancer neoepitopes,
formulation of vaccines constituted by cancer neoepitopes and adjuvant(s),
To be effective, such complex flowchart of activities must be completed in few weeks from the collection of tumor biopsies, a timeline which is fully compatible with BiOMViS’ OMV technology. BiOMViS’ objective is to partner with Biotech/Pharma Companies and bring OMV-based personalized cancer vaccines to patients.
BiOMViS is also interested in partnering with Biotech/Pharma Companies to develop OMV-based vaccines against infectious diseases.
2. High-tech research services in Vaccinology and Immunology BiOMViS Srl offers external partners highly qualified services in several research areas, including molecular and cell biology, microbial fermentation and cell culture, protein purification, immunological assays (ELISA, T cell analyses), FACS, confocal microscopy and models of infectious diseases and cancer.